Positive Six-Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
Favorable patient outcomes from the TANDEM I first-in-human clinical trial of the CroíValve DUO™ System for the percutaneous treatment of tricuspid regurgitation (TR) were presented today by Professor Wojciech Wojakowski at the New York Valves 2024 scientific conference.
- Favorable patient outcomes from the TANDEM I first-in-human clinical trial of the CroíValve DUO™ System for the percutaneous treatment of tricuspid regurgitation (TR) were presented today by Professor Wojciech Wojakowski at the New York Valves 2024 scientific conference.
- View the full release here: https://www.businesswire.com/news/home/20240610037019/en/
W. Wojakowski , New York Valves Jun 2024 (Photo: Business Wire)
TR is a severe heart condition that occurs when the tricuspid valve, on the right side of the heart, fails to close properly. - This results in blood being pumped backwards into the right atrium and venous system causing debilitating symptoms.
- The TANDEM I trial is a prospective, non-randomized, multicenter study designed to evaluate the safety and performance of the DUO System in patients with severe symptomatic TR.